Q-omics provides the consensus-scored MIR6078 profile across patient tissues and cancer cell-line models. MIR6078 expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR6078 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, MIR6078 RNA expression shows 5,935 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRP as cancer lineages where MIR6078 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6078 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6078 survival associations across molecular data types. MIR6078 RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6078 RNA expression–survival associations across cancer types. High MIR6078 expression shows unfavorable associations in STAD, PAAD, LGG and THCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR6078 RNA expression.
This table summarizes MIR6078 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6078. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6078 shows lower tumor expression in KIRP and KIRC. The KIRP box plot shows higher MIR6078 RNA expression in normal versus tumor tissue (log2 FC = −0.156, t-test p = .004).
This table shows molecular features associated with MIR6078 in patient tissues and cancer cell lines. In patient samples, MIR6078 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
